MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Rhea-AI Summary
MaxCyte (Nasdaq: MXCT) announced a technology license partnership with Genentech, a member of the Roche Group, to support development of cell therapy programs. The agreement provides Genentech access to MaxCyte’s ExPERT GTx platform and additional platform technologies across select research, clinical development, and manufacturing workflows.
The multi-program license is designed to enable ex vivo cell engineering applications and streamline progression from early discovery through cGMP manufacturing. According to MaxCyte, the collaboration brings together complementary capabilities in cell engineering, gene editing, and analytical workflows to support next-generation cell-based therapeutics throughout the development lifecycle.
Positive
- Genentech technology license partnership spanning research, clinical development, and manufacturing workflows
- Multi-program license enabling ex vivo cell engineering applications on MaxCyte platforms
Negative
- None.
News Explained
MaxCyte says it has entered into the technology license partnership with Genentech, rather than merely describing a prospective arrangement; Genentech receives access to MaxCyte platforms for selected research, development, and manufacturing workflows across multiple cell-therapy programs.
Market reaction: MXCT +5.13% on Multi-platform technology partnership
On the day this news was published, MXCT gained 5.13%, reflecting a notable positive market reaction. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $125.33M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 15 | Earnings date notice | Neutral | -4.9% | Company scheduled second-quarter 2026 results and conference call for August 12 |
| May 12 | Quarterly earnings | Positive | +24.1% | Reported improved net loss, reiterated guidance, and authorized a share repurchase program |
| Apr 29 | Earnings date notice | Neutral | +7.6% | Scheduled first-quarter 2026 results and investor conference call for May 12 |
| Mar 31 | Inducement grants | Negative | +5.9% | Disclosed stock options and restricted stock units tied to the chief financial officer appointment |
| Mar 24 | Annual earnings report | Negative | -6.8% | Reported declining annual revenue and provided lower 2026 revenue guidance |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
MXCT's recent news reactions were mixed, ranging from -6.81% to +24.06% across earnings, scheduling, and corporate disclosures.
Key Terms
ex vivo medical
cGMP technical
gene editing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows
ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.
The license provides Genentech with access to MaxCyte’s ExPERT GTx® platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to support ex vivo applications for cell engineering.
The capabilities across MaxCyte platform technologies are designed to streamline the advancement of cell therapy programs by providing integrated access to support cell engineering from early discovery to cGMP manufacturing. The partnership with Genentech underscores MaxCyte’s expertise in enabling next-generation cell therapies by bringing together complementary technologies that support both cell engineering and analytical workflows across the development lifecycle.
“Cell therapy development increasingly requires technology partners that can support programs as they advance from research through development and manufacturing,” said Maher Masoud, President and CEO of MaxCyte. “This partnership allows MaxCyte to provide broader support to Genentech across the cell therapy lifecycle by bringing together complementary capabilities in cell engineering and gene editing. Through integrated access to these platforms, we are helping partners move forward with greater speed, confidence, and continuity.”
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing characterization assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine.
Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.
MaxCyte Contacts:
Investor Relations
Gilmartin Group
Erik Abdow
ir@maxcyte.com
Media Contact
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
